|Table of Contents|

Analysis of clinical characteristics of multiple myeloma with non-bone-related extramedullary disease

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 04
Page:
591-594
Research Field:
Publishing date:

Info

Title:
Analysis of clinical characteristics of multiple myeloma with non-bone-related extramedullary disease
Author(s):
Wu Di; Yu Yanli; Liu Fang; Lu Rong; Wang Wenjuan; Hao Jinxia; Wang Mengchang
Department of Hematology，The First Affiliated Hospital of Xi'an Jiaotong University，Shaanxi Xi'an 710061，China.
Keywords:
multiple myeloma; multiple myeloma with non-bone-related extramedullary disease; prognosis
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2018.04.027
Abstract:
Objective:To explore the clinical characteristics of multiple myeloma with non-bone-related extramedullary disease.Methods:The data and follow-up of twenty-six cases (group A) of MM patients with non-bone-related extramedullary disease，one hundred and thirty patients (group B) of MM patients without extramedullary disease and ten patients (group C) of MM patients with bone-related extramedullary disease who were hospitalized in department of hematology，the First Affiliated Hospital of Xi'an Jiaotong University from March 2013 to March 2016 were analyzed retrospectively.The clinical characteristics and prognosis were compared.Results:The incidence of MM with non-bone-related extramedullary disease was 4.68% (26/556)，which involved testicular，spinal epidural，skin and so on.The incidence of bone-related extramedullary disease was 1.80%(10/556).The location of the lesions was near the thoracic wall and the spine beside the ribs.In group A six patients had never remission developed to extramedullary invasion.The median time from diagnosis of MM to extramedullary lesions occurring was 3 (2~12) months.Nine patients obtained remission had extramedullary invasion when plasma cells in bone marrow relapsed as well as no recurrence.The median time from diagnosis of MM to extramedullary lesions occurring was 16.5 (8~45) months.Eleven cases of myeloma were diagnosed associated with extramedullary invasion.The median survival time in group A was 17.2 months，in group B was 37.3 months，and in group C was 35.3 months.Conclusion:Non-bone-related extramedullary disease occurs in MM patients regardless bone marrow remission or not，and develops independent of the bone marrow microenvironmental，which can be used as an independent prognostic factor affect the survival of adverse factors.The prognosis of MM patients with bone-related extramedullary disease is superior to MM patients with non-bone-related extramedullary disease.

References:

［1］Wang L，Zhang YZ.Research progress of multiple myeloma with extramedullary lesions［J］.J Exp Hematol，2016，24(3):945-948.［王路，张翼鷟.伴髓外病变的多发性骨髓瘤研究进展［J］.中国实验血液学杂志，2016，24(3):945-948.］
［2］Bladé J，Fernández de Larrea C，Rosiol L，et al.Soft-tissue plasmacytomas in multiple myeloma:Incidence，mechanisms of extramedullary spread，and treatment approach［J］.J Clin Oncol，2011，29(28):3805-3812.
［3］Deng SH，Xu Y，An G，et al.Clinical analysis of multiple myeloma with simple bone marrow extracranial lesions - data of 834 patients with single center continuity［J］.Chin J Hematol，2015，36(6):501-506.［邓书会，徐燕，安刚，等.多发性骨髓瘤伴单纯骨旁髓外病变临床分析—单中心连续性834例患者资料研究［J］.中华血液学杂志，2015，36(6):501-506.］
［4］Avigdor A，Janani P，Levi I，et al.Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma［J］.Leuk Lymphoma.2001，42(4):683-687.
［5］Yu XC.Prognostic significance of MYC activation in patients with multiple myeloma and its molecular mechanism［D］.Beijing Union Medical College，Chinese Academy of Medical Sciences，Beijing Union Medical College，Chinese Academy of Medical Sciences，Tsinghua University，Department of Medicine，2016.［于晓晨.多发性骨髓瘤髓外病变患者MYC激活的预后意义及其分子机制探讨［D］.北京协和医学院中国医学科学院，北京协和医学院，中国医学科学院，清华大学医学部，2016.］
［6］Sheth N，Yeung J，Chang H.p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma［J］.Leuk Res，2009，33(10):1357-1360.
［7］Pour L，Sevcikova S，Greslikova H，et al.Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse［J］.Haematologica，2013，99(2):360-364.
［8］Wang J，Jing HM，Li M，et al.Clinical analysis and treatment of 14 patients with extramedullary plasmacytoma［J］.Chin J Clin Oncol，2014，11(10):639-642.［王晶，景红梅，李敏，等.14例髓外浆细胞瘤患者的临床特征分析及治疗［J］.中国肿瘤临床，2014，11(10):639-642.］
［9］Kan SS，Liu CS，Liu ZH，et al.Clinical analysis of 25 cases of multiple myeloma with extrapulmonary infiltration［J］.Chin J Lab Diagn，2015(4):672-674.［阚随随，刘春水，刘志何，等.25例初诊伴髓外浸润的多发性骨髓瘤临床分析［J］.中国实验诊断学，2015(4):672-674.］
［10］Huang BH，Li J，Liu JR，et al.Clinical analysis of multiple myeloma complicated with extramedullary infiltration［J］.J Clin Hematol，2011，24(2):151-154.［黄蓓晖，李娟，刘俊茹，等.多发性骨髓瘤并发髓外浸润的临床分析［J］.临床血液学杂志，2011，24(2):151-154.］
［11］Usmani SZ，Heuck C，Mitchell A.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents［J］.Haematologica，2012，97(11):1761-1767.
［12］Papanikolaou X，Repousis P，Tzenou T，et al.Incidence，clinical features，laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse［J］.Leuk Lymphoma，2013；54(7):1459-1464.
［13］Kuang LF，Li J，Huang BH，et al.Therapeutic effect of sequential autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma with extramedullary myopia at the time of initial diagnosis［J］.J Clin Hematol，2016,29(1):24-28.［邝丽芬，李娟，黄蓓晖，等.含硼替佐米方案的诱导治疗序贯自体造血干细胞移植治疗初诊时合并髓外病变的多发性骨髓瘤的疗效分析［J］.临床血液学杂志，2016,29(1):24-28.］
［14］Smith E，Devlin S M，Kosuri S，et al.CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed，high-risk multiple Myeloma［J］.Biol Blood Marrow Transplant，2015，22(2):258-267.

Memo

Memo:
陕西省社会发展科技攻关项目(编号：2016SF-061)
Last Update: 2017-12-29